These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28195541)

  • 1. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
    Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
    J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid.
    Murata Y; Nakajima Y; Sato Y; Hizawa N; Yamakawa D; Matsubara D; Noguchi M; Minami Y
    Jpn J Clin Oncol; 2024 Jun; 54(6):681-688. PubMed ID: 38476004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
    Sakamoto T; Kodani M; Takata M; Chikumi H; Nakamoto M; Nishii-Ito S; Ueda Y; Izumi H; Makino H; Touge H; Takeda K; Yamasaki A; Yanai M; Tanaka N; Igishi T; Shimizu E
    Int J Oncol; 2015 Apr; 46(4):1473-80. PubMed ID: 25651992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.
    Asaka S; Yoshizawa A; Saito K; Kobayashi Y; Yamamoto H; Negishi T; Nakata R; Matsuda K; Yamaguchi A; Honda T
    Int J Oncol; 2018 Jun; 52(6):2110-2118. PubMed ID: 29620164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings.
    Kawahara A; Fukumitsu C; Taira T; Abe H; Takase Y; Murata K; Yamaguchi T; Azuma K; Ishii H; Takamori S; Akiba J; Hoshino T; Kage M
    Cancer Cytopathol; 2015 Oct; 123(10):620-8. PubMed ID: 26235264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
    Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
    Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Kobayashi N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2012 Sep; 7(9):1369-81. PubMed ID: 22858585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
    Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
    Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
    Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
    J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
    Kim CG; Shim HS; Hong MH; Cha YJ; Heo SJ; Park HS; Kim JH; Lee JG; Lee CY; Cho BC; Kim HR
    Oncotarget; 2017 Sep; 8(39):65111-65122. PubMed ID: 29029416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
    Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
    Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting
    Jeon SH; Kim HW; Kim BN; Kang N; Yeo CD; Park CK; Kim YK; Lee YH; Kim TJ; Lee KY; Lee SH; Park JY; Park MS; Yim HW; Kim SJ
    In Vivo; 2019; 33(2):595-603. PubMed ID: 30804147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
    Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
    J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
    Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
    Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.